Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 902Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 489Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 243Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

infigratinib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Renal Pelvis and Ureter Urothelial Carcinoma × Clear all
NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡